Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Report 2026
Download Free Sample Buy Now
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Global Report 2026 Market Report Infographic Image

Published : March 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Report 2026

Global Outlook – By Drugs (Tetrabenazine, Deutetrabenazine, Valbenazine, Other Drugs), By Route Of Administration (Oral, Other Administrations), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By Application (Huntington’s Disease, Tardive Dyskinesia, Other Applications), By End User (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, Strategies, and Forecast to 2035

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Purchase This Report Download Sample PDF
Item added to cart!

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

• Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor market size has reached to $1.25 billion in 2025

• Expected to grow to $2.01 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%

• Growth Driver: Rising Parkinson's Disease Prevalence Driving Growth In The Market

• Market Trend: Innovative Capsule Formulations In The Market

• North America was the largest region in 2025.

What Is Covered Under Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?

A vesicular monoamine transporter 2 (VMAT2) inhibitor is a drug that blocks VMAT2, a protein responsible for transporting monoamines (dopamine, serotonin, norepinephrine) into synaptic vesicles for release in the brain. VMAT2 inhibitors are utilized to manage neurological and psychiatric disorders by reducing excessive neurotransmitter release, particularly dopamine, to treat conditions such as tardive dyskinesia, Huntington’s disease, and other hyperkinetic movement disorders.

The main drugs in the vesicular monoamine transporter 2 (VMAT2) inhibitor are tetrabenazine, deutetrabenazine, valbenazine, and other drugs. Tetrabenazine is a VMAT2 inhibitor used to treat movement disorders by reducing dopamine levels in the brain. These drugs are administered through various routes, such as oral and other administrations, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. They are used for various applications, including Huntington’s disease, tardive dyskinesia, and other conditions. The primary end users of these drugs include hospitals, homecare settings, specialty clinics, and other healthcare facilities.

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Global Report 2026 Market Report bar graph

What Is The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Size and Share 2026?

The vesicular monoamine transporter 2 (vmat2) inhibitor market size has grown rapidly in recent years. It will grow from $1.25 billion in 2025 to $1.37 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to approval of tetrabenazine, rising antipsychotic usage, increased movement disorder diagnosis, hospital-based neurology care, limited alternative therapies.

What Is The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Growth Forecast?

The vesicular monoamine transporter 2 (vmat2) inhibitor market size is expected to see strong growth in the next few years. It will grow to $2.01 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to growing tardive dyskinesia prevalence, expansion of deutetrabenazine usage, rising neurological disorder awareness, growth of specialty neurology clinics, increased oral drug preference. Major trends in the forecast period include rising use of targeted neurotransmitter modulation, increasing treatment of tardive dyskinesia, expansion of oral neurological therapies, growing focus on movement disorder management, increased adoption of long-term neurology drugs.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Segmentation

1) By Drugs: Tetrabenazine, Deutetrabenazine, Valbenazine, Other Drugs

2) By Route Of Administration: Oral, Other Administrations

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By Application: Huntington’s Disease, Tardive Dyskinesia, Other Applications

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Tetrabenazine: Huntington’s Disease Treatment, Tardive Dyskinesia Management, Tourette Syndrome Treatment

2) By Deutetrabenazine: Huntington’s Disease Chorea, Tardive Dyskinesia Treatment, Off-Label Movement Disorders

3) By Valbenazine: Tardive Dyskinesia Treatment, Tourette Syndrome Research, Other Hyperkinetic Movement Disorders

4) By Other Drugs: Investigational VMAT2 Inhibitors, Emerging Therapies For Movement Disorders, Off-Label Use In Neurological Conditions

What Is The Driver Of The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?

The increasing prevalence of parkinson’s disease is expected to propel the growth of the vesicular monoamine transporter 2 (VMAT2) inhibitor market going forward. Parkinson's disease refers to a progressive neurological disorder that affects movement due to the loss of dopamine-producing cells in the brain. The increasing prevalence of parkinson's disease is mainly due to an aging population, better diagnosis, environmental factors such as toxins, genetic influences, and greater awareness of the condition. VMAT2 inhibitors help manage Parkinson's symptoms by controlling dopamine release and reducing tremors and dyskinesia. For instance, in October 2025, according to the Parkinson's UK, a UK-based research and support charity, by 2030, Parkinson’s cases in the UK are expected to reach 173,000, and around 28,000 people are projected to be diagnosed in 2025, which means one new diagnosis every 20 minutes as the population grows and ages. Therefore, the increased prevalence of Parkinson’s disease is driving growth in the vesicular monoamine transporter 2 (VMAT2) inhibitor industry.

Key Players In The Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

Major companies operating in the vesicular monoamine transporter 2 (vmat2) inhibitor market are Neurocrine Biosciences Inc., H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Bausch Health Companies Inc., Luye Pharma Group Ltd., Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Eli Lilly and Company, Merck KGaA, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Biogen Inc

Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Trends and Insights

Major companies operating in the vesicular monoamine transporter 2 (VMAT2) inhibitors market are focusing on developing innovative formulations such as capsules to enhance patient compliance, improve drug stability, and optimize therapeutic efficacy. Capsules, a solid dosage form enclosed in a gelatin or HPMC shell, help VMAT2 inhibitors by improving drug stability, ensuring precise dosing, and enhancing patient compliance. For instance, in July 2024, Neurocrine Biosciences Inc., a US-based biopharmaceutical company, launched Ingrezza Sprinkle (valbenazine) capsules, a new formulation of the VMAT2 inhibitor Ingrezza designed to ease administration for adults with tardive dyskinesia and chorea associated with Huntington's disease who experience dysphagia or difficulty swallowing. Ingrezza Sprinkle offers the same effective dosing options as Ingrezza and can be administered by sprinkling the contents of the capsule onto soft food or by swallowing the capsule whole.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?

In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. With this acquisition, Bristol Myers Squibb aims to strengthen its neurology portfolio by gaining access to Karuna Therapeutics' promising pipeline of innovative treatments, including the VMAT2 inhibitor KarXT, which has the potential to address unmet needs in psychiatric disorders such as schizophrenia, thereby expanding its therapeutic offerings and accelerating growth in the neuroscience sector. Karuna Therapeutics is a US-based biopharmaceutical company that offers vesicular monoamine transporter 2 (VMAT2) inhibitor treatment.

Regional Insights

North America was the largest region in the vesicular monoamine transporter 2 (VMAT2) inhibitor market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?

The vesicular monoamine transporter 2 (VMAT2) inhibitor market consists of sales of products such as deutetrabenazine, valbenazine, and tetrabenazine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Report 2026?

The vesicular monoamine transporter 2 (vmat2) inhibitor market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vesicular monoamine transporter 2 (vmat2) inhibitor industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $1.37 billion
Revenue Forecast In 2035 $2.01 billion
Growth Rate CAGR of 10.2% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Drugs, Route Of Administration, Distribution Channel, Application, End User
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Neurocrine Biosciences Inc., H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Bausch Health Companies Inc., Luye Pharma Group Ltd., Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma, Dr. Reddy’s L
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Rising Use Of Targeted Neurotransmitter Modulation

4.2.2 Increasing Treatment Of Tardive Dyskinesia

4.2.3 Expansion Of Oral Neurological Therapies

4.2.4 Growing Focus On Movement Disorder Management

4.2.5 Increased Adoption Of Long-Term Neurology Drugs

5. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Neurology Clinics

5.3 Specialty Clinics

5.4 Retail Pharmacies

5.5 Homecare Patients

6. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Size, Comparisons And Growth Rate Analysis

7.3. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Segmentation

9.1. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Tetrabenazine, Deutetrabenazine, Valbenazine, Other Drugs

9.2. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Oral, Other Administrations

9.3. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

9.4. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Huntington’s Disease, Tardive Dyskinesia, Other Applications

9.5. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Homecare, Specialty Clinics, Other End Users

9.6. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Tetrabenazine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Huntington’s Disease Treatment, Tardive Dyskinesia Management, Tourette Syndrome Treatment

9.7. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Deutetrabenazine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Huntington’s Disease Chorea, Tardive Dyskinesia Treatment, Off-Label Movement Disorders

9.8. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Valbenazine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Tardive Dyskinesia Treatment, Tourette Syndrome Research, Other Hyperkinetic Movement Disorders

9.9. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Investigational VMAT2 Inhibitors, Emerging Therapies For Movement Disorders, Off-Label Use In Neurological Conditions

10. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Regional And Country Analysis

10.1. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

11.1. Asia-Pacific Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

12.1. China Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

13.1. India Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

14.1. Japan Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

15.1. Australia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

16.1. Indonesia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

17.1. South Korea Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

18.1. Taiwan Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

19.1. South East Asia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

20.1. Western Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

21.1. UK Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

22.1. Germany Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

23.1. France Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

24.1. Italy Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

25.1. Spain Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

26.1. Eastern Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

27.1. Russia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

28.1. North America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

29.1. USA Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

30.1. Canada Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

31.1. South America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

32.1. Brazil Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

33.1. Middle East Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

34.1. Africa Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Regulatory and Investment Landscape

36. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Competitive Landscape And Company Profiles

36.1. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Company Profiles

36.3.1. Neurocrine Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. H. Lundbeck A/S Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Sun Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Other Major And Innovative Companies

Luye Pharma Group Ltd., Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Eli Lilly and Company, Merck KGaA, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Biogen Inc

38. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

40. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market High Potential Countries, Segments and Strategies

40.1 Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market In 2030 - Countries Offering Most New Opportunities

40.2 Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market In 2030 - Segments Offering Most New Opportunities

40.3 Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Overview Of Key Products - Product Examples
  • Table 2: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Supply Chain Analysis
  • Table 4: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Major Raw Material Providers
  • Table 5: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Major Resource Providers
  • Table 6: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Major Manufacturers (Suppliers)
  • Table 7: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Major Distributors And Channel Partners
  • Table 8: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Key Technologies & Future Trends
  • Table 9: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Major Trends
  • Table 10: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Major End Users
  • Table 11: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market - TAM, US$ Billion, 2025
  • Table 15: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Tetrabenazine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Deutetrabenazine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Valbenazine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: Asia-Pacific, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: Asia-Pacific, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: China, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: China, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: India, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: India, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Japan, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Japan, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Australia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Australia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: Indonesia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: Indonesia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: South Korea, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: South Korea, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: Taiwan, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: Taiwan, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: South East Asia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: South East Asia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: Western Europe, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: Western Europe, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: UK, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: UK, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: Germany, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: Germany, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: France, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: France, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Italy, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Italy, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Spain, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Spain, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Eastern Europe, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Eastern Europe, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: Russia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: Russia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: North America, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: North America, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: USA, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: USA, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: Canada, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: Canada, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: South America, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: South America, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Brazil, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Brazil, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Middle East, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Middle East, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Africa, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 97: Africa, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 98: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 99: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market - Company Scoring Matrix
  • Table 100: Neurocrine Biosciences Inc. Financial Performance
  • Table 101: H. Lundbeck A/S Financial Performance
  • Table 102: Teva Pharmaceutical Industries Ltd. Financial Performance
  • Table 103: Sun Pharmaceutical Industries Limited Financial Performance
  • Table 104: Bausch Health Companies Inc. Financial Performance
  • Table 105: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Competitive Benchmarking (In USD Billions)
  • Table 106: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Competitive Dashboard
  • Table 107: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 108: Global, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Size Gain ($ Billion), Segmentation By Drugs, 2025 – 2030
  • Table 109: Global, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030
  • Table 110: Global, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

List Of Figures

    Figure 1: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Supply Chain Analysis
  • Figure 4: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Major Raw Material Providers
  • Figure 5: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Major Resource Providers
  • Figure 6: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Major Distributors And Channel Partners
  • Figure 8: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Key Technologies & Future Trends
  • Figure 9: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Major Trends
  • Figure 10: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Major End Users
  • Figure 11: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market - TAM, US$ Billion, 2025
  • Figure 15: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Tetrabenazine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Deutetrabenazine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Valbenazine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: Asia-Pacific, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: Asia-Pacific, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: China, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: China, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: India, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: India, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Japan, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Japan, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Australia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Australia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: Indonesia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: Indonesia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: South Korea, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: South Korea, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: Taiwan, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: Taiwan, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: South East Asia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: South East Asia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: Western Europe, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: Western Europe, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: UK, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: UK, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: Germany, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: Germany, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: France, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: France, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Italy, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Italy, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Spain, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Spain, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Eastern Europe, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Eastern Europe, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: Russia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: Russia, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: North America, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: North America, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: USA, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: USA, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: Canada, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: Canada, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: South America, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: South America, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Brazil, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Brazil, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Middle East, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Middle East, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Africa, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 97: Africa, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 98: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 99: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market - Company Scoring Matrix
  • Figure 100: Neurocrine Biosciences Inc. Financial Performance
  • Figure 101: H. Lundbeck A/S Financial Performance
  • Figure 102: Teva Pharmaceutical Industries Ltd. Financial Performance
  • Figure 103: Sun Pharmaceutical Industries Limited Financial Performance
  • Figure 104: Bausch Health Companies Inc. Financial Performance
  • Figure 105: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Competitive Benchmarking (In USD Billions)
  • Figure 106: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market, Competitive Dashboard
  • Figure 107: Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 108: Global, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Size Gain ($ Billion), Segmentation By Drugs, 2025 – 2030
  • Figure 109: Global, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030
  • Figure 110: Global, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Read More About Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

Read More About Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Read More About 2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Read More About Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Read More About CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Read More About Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Read More About Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Peripheral Vasodilator Drugs Market Report 2026 - Global Outlook – By Drug Type (Calcium Channel Blockers, Direct-Acting Vasodilators, Alpha-Adrenergic Blockers, Potassium Channel Activators, Nitrates, Other Types), By I...

Anti-Parkinson Drugs Market Report 2026 - Global Outlook – By Drugs Class (Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, A...

Anticholinergic Drugs Market Report 2026 - Global Outlook – By Type (Synthetic Compounds, Natural, Semi-Synthetic Compounds), By Route Of Administration (Parental, Oral, Topical), By Application (Overactive Bladder, Park...

Cholinergic Drugs Market Report 2026 - Global Outlook – By Type (Powder, Tablet, Capsule), By Drug Type (Muscarinic Agonists, Nicotinic Agonists, Acetylcholinesterase Inhibitors), By Indication (Alzheimer's Disease, Myas...

Methenamine Hippurate Tablets Market Report 2026 - Global Outlook – By Type (20 Tablets Or Bottle, 6 Tablets Or Bottle), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By Application (Unco...

mTOR Inhibitors Market Report 2026 - Global Outlook – By Product Type (Rapamune, Afinitor, Torisel, Zortress, Other Product Types), By Indication (Oncology, Immunosuppressant, Organ Transplantation, Other Indications), B...

Central Nervous System Drugs Global Market Report 2022 – By Type (Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route O...

Anti-Infective Drugs Market - By Type (Antibiotics, Antivirals, Antifungals), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classifi...

Frequently Asked Questions

The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor market was valued at $1.25 billion in 2025, increased to $1.37 billion in 2026, and is projected to reach $2.01 billion by 2030.

The global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor market is expected to grow at a CAGR of 9.9% from 2026 to 2035 to reach $2.01 billion by 2035.

Some Key Players in the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor market Include, Neurocrine Biosciences Inc., H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Bausch Health Companies Inc., Luye Pharma Group Ltd., Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Eli Lilly and Company, Merck KGaA, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Biogen Inc .

Major trend in this market includes: Innovative Capsule Formulations In The Market. For further insights on this market. request a sample here

North America was the largest region in the vesicular monoamine transporter 2 (VMAT2) inhibitor market in 2025. The regions covered in the vesicular monoamine transporter 2 (vmat2) inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us